Literature DB >> 3477296

Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease.

A C Martens1, F W Schultz, A Hagenbeek.   

Abstract

In a rat model (BNML) for human acute myelocytic leukemia the distribution of leukemic cells in bone marrow samples from various sites was investigated, using monoclonal antibodies (MoAbs) and flow cytometry. Rats were studied before chemotherapy as well as thereafter, ie, in the "minimal residual disease" (MRD) phase. Bone marrow from different types of bones was analyzed from each animal. Before treatment, the ratio of the measured extreme values (ie, highest/lowest value) for leukemic cell frequencies in bones from individual rats ranged from 3.7 to 11.7. During the MRD phase the ratios of the extremes ranged from a factor of 36 to more than 13,000 from one rat to another. The variability between bones of comparable size was estimated by studying the ribs from each individual animal. Within individuals the extremes differed by a factor of 1.2 to 4.0 before chemotherapy and from 2.4 to greater than 320 after chemotherapy. The variability within the marrow cavity of a single bone was determined by analyzing multiple samples from femoral bones cut into slices. The leukemic cell frequency appeared to vary considerably, ie, before treatment from 1.7 to 7.3 and during MRD from 4 to 28,000. The presented data may contribute to understanding the sometimes conflicting observations in leukemic patients. Improvement of methods for detecting MRD will not automatically lead to a more accurate estimation of the total tumor burden. The reliability of diagnoses based on the analysis of single bone marrow aspirates appears to be highly questionable.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3477296

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

Review 2.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

3.  Localized relapse in bone marrow in a posttransplantation patient with t(6;9) acute myeloid leukemia.

Authors:  Tetsuo Maeda; Satoru Kosugi; Hidetoshi Ujiie; Kazuoki Osumi; Takashi Fukui; Hitoshi Yoshida; Hirokazu Kashiwagi; Jun Ishikawa; Yoshiaki Tomiyama; Yuji Matsuzawa
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

Review 4.  Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

5.  Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation.

Authors:  Megan Othus; Robert Peter Gale; Christopher S Hourigan; Roland B Walter
Journal:  Bone Marrow Transplant       Date:  2019-10-30       Impact factor: 5.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.